PALO ALTO, Calif.--Incyte Pharmaceuticals has completed its acquisition of the gene expression microarray company Synteni that was announced in December. The transaction involves Incyte's issuing shares of its common stock in exchange for all of Synteni's outstanding equity.
"The integration of Synteni's proven microarray technology and Incyte's genomic information is well underway," commented Randy Scott, Incyte's president and chief scientific officer. "We have already identified and initiated development of a series of new microarray products for launch beginning this year, including two microarrays with applications in pharmacology and toxicology and a panel of microarrays comprising Incyte's entire set of human genes. Combined with Incyte's efforts to identify every human gene, this program should enable us to provide our pharmaceutical partners with the ability to scan virtually every gene in the human genome across any biological sample by the year 2000."